EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Evidence-Based Medicine 2007;12:79; doi:10.1136/ebm.12.3.79
Copyright © 2007 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saad, R. J
Right arrow Articles by Chey, W. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saad, R. J
Right arrow Articles by Chey, W. D

Therapeutics

Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia

Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(4):CD001960.[Medline]

Q In patients with non-ulcer dyspepsia (NUD), do antacids, histamine H2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), prokinetics (PROK), mucosal protecting agents (MPAs), and antimuscarinics improve symptoms?

Clinical impact ratings GP/FP/Primary care ******{star} Gastroenterology ******* Internal medicine ******{star}

Key Words: dyspepsia • gastrointestinal agents

The first 150 words of the full text of this article appear below.

METHODS
Formula Data sources: Medline (1966 to January 2006), CINAHL (1982 to January 2006), EMBASE/Excerpta Medica (1988 to January 2006), Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2005), SIGLE, bibliographies of relevant studies, experts in the field, and pharmaceutical companies.

Formula Study selection and assessment: randomised controlled trials (RCTs) that compared antacids, H2RAs, PPIs, PROK, MPAs, or antimuscarinics with placebo or other drugs in patients with symptoms of NUD and no significant findings on endoscopy or barium studies. Studies of patients who had peptic ulcer disease, pancreato-biliary disease, neoplastic disease, oesophagitis, non-steroidal anti-inflammatory drug induced or metabolic disorders, reflux symptoms or heartburn, or duodenitis (in >10% patients) were excluded. 73 RCTs met selection criteria: 19 RCTs (n = 3178) evaluated PROK, 12 RCTs (n = 2183) evaluated H2RAs, and 10 RCTs (n = 3347) evaluated PPIs. Quality assessment was based on randomisation, allocation concealment, and blinding. Funnel plot . . . [Full text of this article]

Richard J Saad, MD, William D Chey, MD, AGAF, FACG, FACP

University of Michigan, Ann Arbor, Michigan, USA






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd.